secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001193125-21-325991
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q3 2021 net loss $22.0M; cash $791.8M; NUV-422 enrollment ongoing
------------------------------------------------------------------------------

- Net loss of $22.0M ($0.11 per share) vs $11.0M ($0.12) in Q3 2020.
- R&D expenses $17.1M, up from $8.6M; G&A $5.7M, up from $2.9M.
- Cash, equivalents and marketable securities $791.8M as of Sept 30, 2021.
- Enrollment ongoing in Phase 1/2 study of NUV-422; top-line data expected 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/0001193125-21-325991-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312521325991/d439428d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-325991

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer